{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:57:18Z","timestamp":1787669838329,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1I1A1A01041517"],"award-info":[{"award-number":["NRF-2021R1I1A1A01041517"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-025-02614-0","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T12:34:23Z","timestamp":1768480463000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["ORY1001 enhances anti-tumor immunity via CXCL10-mediated macrophage modulation in EBV-positive DLBCL"],"prefix":"10.1186","volume":"24","author":[{"given":"Joo Hyun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon Ji","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Eun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Seog","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"issue":"7","key":"2614_CR1","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1002\/ajh.26579","volume":"97","author":"L Malpica","year":"2022","unstructured":"Malpica L, Marques-Piubelli ML, Beltran BE, Chavez JC, Miranda RN, Castillo JJ. EBV-positive diffuse large B-cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk-stratification, and management. Am J Hematol. 2022;97(7):951\u201365.","journal-title":"Am J Hematol"},{"key":"2614_CR2","doi-asserted-by":"crossref","unstructured":"Andrei G, Trompet E, Snoeck R. Novel therapeutics for Epstein\u207bBarr virus. Molecules. 2019;24(5):997.","DOI":"10.3390\/molecules24050997"},{"key":"2614_CR3","doi-asserted-by":"publisher","first-page":"976196","DOI":"10.3389\/fimmu.2022.976196","volume":"13","author":"SMP Vadevoo","year":"2022","unstructured":"Vadevoo SMP, Gunassekaran GR, Yoo JD, Kwon TH, Hur K, Chae S, et al. Epigenetic therapy reprograms M2-type tumor-associated macrophages into an M1-like phenotype by upregulating miR-7083-5p. Front Immunol. 2022;13:976196.","journal-title":"Front Immunol"},{"issue":"11","key":"2614_CR4","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21(11):799\u2013820.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"2614_CR5","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41375-022-01804-w","volume":"37","author":"F Frontzek","year":"2023","unstructured":"Frontzek F, Staiger AM, Wullenkord R, Grau M, Zapukhlyak M, Kurz KS, et al. Molecular profiling of EBV associated diffuse large B-cell lymphoma. Leukemia. 2023;37(3):670\u20139.","journal-title":"Leukemia"},{"issue":"21","key":"2614_CR6","doi-asserted-by":"publisher","first-page":"4338","DOI":"10.1182\/bloodadvances.2021004203","volume":"5","author":"B Manfroi","year":"2021","unstructured":"Manfroi B, De Grandis M, Moreaux J, Tabruyn S, Mayol JF, Quintero M, et al. The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5. Blood Adv. 2021;5(21):4338\u201351.","journal-title":"Blood Adv"},{"issue":"9","key":"2614_CR7","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1038\/s41374-020-0441-4","volume":"100","author":"T Kodama","year":"2020","unstructured":"Kodama T, Koma YI, Arai N, Kido A, Urakawa N, Nishio M, et al. CCL3-CCR5 axis contributes to progression of esophageal squamous cell carcinoma by promoting cell migration and invasion via Akt and ERK pathways. Lab Invest. 2020;100(9):1140\u201357.","journal-title":"Lab Invest"},{"issue":"14","key":"2614_CR8","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1182\/bloodadvances.2020003871","volume":"5","author":"K Le","year":"2021","unstructured":"Le K, Sun J, Khawaja H, Shibata M, Maggirwar SB, Smith MR, et al. Mantle cell lymphoma polarizes tumor-associated macrophages into M2-like macrophages, which in turn promote tumorigenesis. Blood Adv. 2021;5(14):2863\u201378.","journal-title":"Blood Adv"},{"issue":"9","key":"2614_CR9","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/s41419-020-02925-9","volume":"11","author":"B Zhang","year":"2020","unstructured":"Zhang B, Miao T, Shen X, Bao L, Zhang C, Yan C, et al. EB virus-induced ATR activation accelerates nasopharyngeal carcinoma growth via M2-type macrophages polarization. Cell Death Dis. 2020;11(9):742.","journal-title":"Cell Death Dis"},{"issue":"4","key":"2614_CR10","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/1878-0261.12644","volume":"14","author":"H Dan","year":"2020","unstructured":"Dan H, Liu S, Liu J, Liu D, Yin F, Wei Z, et al. RACK1 promotes cancer progression by increasing the M2\/M1 macrophage ratio via the NF-\u03baB pathway in oral squamous cell carcinoma. Mol Oncol. 2020;14(4):795\u2013807.","journal-title":"Mol Oncol"},{"issue":"3","key":"2614_CR11","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41388-018-0451-5","volume":"38","author":"Y Qin","year":"2019","unstructured":"Qin Y, Vasilatos SN, Chen L, Wu H, Cao Z, Fu Y, et al. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint Blockade. Oncogene. 2019;38(3):390\u2013405.","journal-title":"Oncogene"},{"key":"2614_CR12","doi-asserted-by":"publisher","first-page":"1251648","DOI":"10.3389\/fimmu.2023.1251648","volume":"14","author":"L Yang","year":"2023","unstructured":"Yang L, Han P, Cui T, Miao Y, Zhao T, Cui Z, et al. M2 macrophage inhibits the antitumor effects of lenvatinib on intrahepatic cholangiocarcinoma. Front Immunol. 2023;14:1251648.","journal-title":"Front Immunol"},{"issue":"2","key":"2614_CR13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1158\/1078-0432.CCR-19-1868","volume":"26","author":"IG House","year":"2020","unstructured":"House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, et al. Macrophage-Derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint Blockade. Clin Cancer Res. 2020;26(2):487\u2013504.","journal-title":"Clin Cancer Res"},{"key":"2614_CR14","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, et al. CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat Rev. 2018;63:40\u20137.","journal-title":"Cancer Treat Rev"},{"issue":"8","key":"2614_CR15","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1038\/s41380-022-01508-8","volume":"27","author":"M Rapanelli","year":"2022","unstructured":"Rapanelli M, Williams JB, Ma K, Yang F, Zhong P, Patel R, et al. Targeting histone demethylase LSD1 for treatment of deficits in autism mouse models. Mol Psychiatry. 2022;27(8):3355\u201366.","journal-title":"Mol Psychiatry"},{"issue":"5","key":"2614_CR16","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1007\/s00277-023-05395-z","volume":"103","author":"S Zhuang","year":"2024","unstructured":"Zhuang S, Yang Z, Cui Z, Zhang Y, Che F. Epigenetic alterations and advancement of lymphoma treatment. Ann Hematol. 2024;103(5):1435\u201354.","journal-title":"Ann Hematol"},{"issue":"1","key":"2614_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12943-023-01768-0","volume":"22","author":"Z Liu","year":"2023","unstructured":"Liu Z, Li X, Gao Y, Liu J, Feng Y, Liu Y, et al. Epigenetic reprogramming of Runx3 reinforces CD8\u2009+\u2009T-cell function and improves the clinical response to immunotherapy. Mol Cancer. 2023;22(1):84.","journal-title":"Mol Cancer"},{"issue":"6","key":"2614_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41419-023-05878-x","volume":"14","author":"S Long","year":"2023","unstructured":"Long S, Huang G, Ouyang M, Xiao K, Zhou H, Hou A, et al. Epigenetically modified AP-2\u03b1 by DNA methyltransferase facilitates glioma immune evasion by upregulating PD-L1 expression. Cell Death Dis. 2023;14(6):365.","journal-title":"Cell Death Dis"},{"key":"2614_CR19","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3389\/fimmu.2019.01351","volume":"10","author":"AHY Tan","year":"2019","unstructured":"Tan AHY, Tu W, McCuaig R, Hardy K, Donovan T, Tsimbalyuk S, et al. Lysine-Specific histone demethylase 1A regulates macrophage polarization and checkpoint molecules in the tumor microenvironment of Triple-Negative breast cancer. Front Immunol. 2019;10:1351.","journal-title":"Front Immunol"},{"issue":"1","key":"2614_CR20","doi-asserted-by":"publisher","first-page":"6764","DOI":"10.1038\/s41598-024-55113-6","volume":"14","author":"JH Kim","year":"2024","unstructured":"Kim JH, Park C, Kim WS. Lysine demethylase LSD1 is associated with stemness in EBV-positive B cell lymphoma. Sci Rep. 2024;14(1):6764.","journal-title":"Sci Rep"},{"issue":"1","key":"2614_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s13045-019-0811-9","volume":"12","author":"Y Fang","year":"2019","unstructured":"Fang Y, Liao G, Yu B. LSD1\/KDM1A inhibitors in clinical trials: advances and prospects. J Hematol Oncol. 2019;12(1):129.","journal-title":"J Hematol Oncol"},{"issue":"9","key":"2614_CR22","doi-asserted-by":"publisher","first-page":"101441","DOI":"10.1016\/j.isci.2020.101441","volume":"23","author":"AY Sarode","year":"2020","unstructured":"Sarode AY, Jha MK, Zutshi S, Ghosh SK, Mahor H, Sarma U, et al. Residue-Specific message encoding in CD40-Ligand. iScience. 2020;23(9):101441.","journal-title":"iScience"},{"issue":"1","key":"2614_CR23","doi-asserted-by":"publisher","first-page":"172","DOI":"10.20892\/j.issn.2095-3941.2020.0211","volume":"18","author":"H Xu","year":"2021","unstructured":"Xu H, Li D, Ma J, Zhao Y, Xu L, Tian R, et al. The IL-33\/ST2 axis affects tumor growth by regulating mitophagy in macrophages and reprogramming their polarization. Cancer Biol Med. 2021;18(1):172\u201383.","journal-title":"Cancer Biol Med"},{"issue":"14","key":"2614_CR24","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1158\/0008-5472.CAN-19-3265","volume":"80","author":"Z Xiao","year":"2020","unstructured":"Xiao Z, Mayer AT, Nobashi TW, Gambhir SS. ICOS is an indicator of T-cell-Mediated response to cancer immunotherapy. Cancer Res. 2020;80(14):3023\u201332.","journal-title":"Cancer Res"},{"issue":"5","key":"2614_CR25","doi-asserted-by":"publisher","first-page":"109955","DOI":"10.1016\/j.celrep.2021.109955","volume":"37","author":"L He","year":"2021","unstructured":"He L, Jhong JH, Chen Q, Huang KY, Strittmatter K, Kreuzer J, et al. Global characterization of macrophage polarization mechanisms and identification of M2-type polarization inhibitors. Cell Rep. 2021;37(5):109955.","journal-title":"Cell Rep"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02614-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02614-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02614-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T01:08:19Z","timestamp":1770772099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-025-02614-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,15]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2614"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02614-0","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,15]]},"assertion":[{"value":"12 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Human peripheral blood mononuclear cells (PBMCs) were isolated from anonymous healthy donors. Whole blood samples were collected in accordance with the protocols approved by the Institutional Review Boards of Samsung Medical Center (SMC) (IRB No. 2022-12-139). Also, all animal experiments were conducted with the approvals of Institutional Animal Care and Use Committee (IACUC) and SMC (A24-044).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}